MEGGLE USA appoints new CEO

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE has announced the appointment of Lewis Jackson as CEO of its American subsidiary MEGGLE USA Inc.

Mr. Jackson, an experienced business leader, succeeds Ruth Leinenbach in the role, effective from June 12, reporting to the Managing Director of MEGGLE Ingredients, Marcus Hormuth.

Ms. Leinenbach has presided over strong development of the US affiliate, headquartered at Pawling, NY.  She will continue to work closely with MEGGLE USA as Director Business Unit Excipients.

US track record

Lewis Jackson has many years of global business leadership experience in the pharmaceutical industry, having held several executive positions in the United States.

Ruth Leinenbach commented: “We are delighted to welcome Lewis Jackson, an insightful and decisive leader with a long track record of success, to MEGGLE USA. Mr. Jackson will bring a wealth of international pharmaceutical industry experience and a broad range of industry relationships.”

“We are confident that Mr. Jackson is very well positioned to further grow the Excipient business for MEGGLE”, Ms. Leinenbach added.

About MEGGLE

Bavarian-based MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several revolutionary products, notably Tablettose®, the world’s first agglomerated lactose grade for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

Resources

Click on MEGGLE USA appoints Lewis Jackson as new CEO to see original announcement.